These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12604546)

  • 1. Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model.
    MacGowan AP; Rogers CA; Holt HA; Bowker KE
    Antimicrob Agents Chemother; 2003 Mar; 47(3):1088-95. PubMed ID: 12604546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model.
    Zelenitsky SA; Ariano RE; Iacovides H; Sun S; Harding GK
    J Antimicrob Chemother; 2003 Apr; 51(4):905-11. PubMed ID: 12654762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae.
    Florea NR; Tessier PR; Zhang C; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2004 Apr; 48(4):1215-21. PubMed ID: 15047522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of different antibacterial effect measures used in in vitro models of infection and subsequent use in pharmacodynamic correlations for moxifloxacin.
    MacGowan A; Rogers C; Holt HA; Wootton M; Bowker K
    J Antimicrob Chemother; 2000 Jul; 46(1):73-8. PubMed ID: 10882692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and pharmacodynamic predictors of antimicrobial efficacy: moxifloxacin and Streptococcus pneumoniae.
    Schentag JJ
    J Chemother; 2002 Feb; 14 Suppl 2():13-21. PubMed ID: 12003136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
    Xuan D; Zhong M; Mattoes H; Bui KQ; McNabb J; Nicolau DP; Quintiliani R; Nightingale CH
    Antimicrob Agents Chemother; 2001 Mar; 45(3):794-9. PubMed ID: 11181363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploration of the in-vitro pharmacodynamic activity of moxifloxacin for Staphylococcus aureus and Streptococci of lancefield groups A and G.
    MacGowan AP; Bowker KE; Wootton M; Holt HA
    J Antimicrob Chemother; 1999 Dec; 44(6):761-6. PubMed ID: 10590276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection.
    MacGowan AP; Rogers CA; Holt HA; Wootton M; Bowker KE
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2916-21. PubMed ID: 11557490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.
    Allen GP; Kaatz GW; Rybak MJ
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2606-14. PubMed ID: 12878526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.
    Madaras-Kelly KJ; Ostergaard BE; Hovde LB; Rotschafer JC
    Antimicrob Agents Chemother; 1996 Mar; 40(3):627-32. PubMed ID: 8851583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of moxifloxacin, administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection.
    MacGowan AP; Bowker KE; Wootton M; Holt HA
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1560-4. PubMed ID: 10390203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model.
    Ba BB; Feghali H; Arpin C; Saux MC; Quentin C
    Antimicrob Agents Chemother; 2004 Mar; 48(3):946-53. PubMed ID: 14982788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3935-41. PubMed ID: 14638504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
    LaPlante KL; Rybak MJ; Tsuji B; Lodise TP; Kaatz GW
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1315-20. PubMed ID: 17296740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses.
    Firsov AA; Lubenko IY; Vostrov SN; Kononenko OV; Zinner SH; Portnoy YA
    J Antimicrob Chemother; 2000 Nov; 46(5):725-32. PubMed ID: 11062191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis.
    Yoshida K; Okimoto N; Kishimoto M; Fukano H; Hara H; Yoneyama H; Moriya O; Kawanishi M; Kimura M; Matsushima T; Niki Y
    J Infect Chemother; 2011 Oct; 17(5):678-85. PubMed ID: 21847518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
    Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
    Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
    J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1665-70. PubMed ID: 12019073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.